EP0792098A1 - Enhancing growth and pearl production in mollusks - Google Patents
Enhancing growth and pearl production in mollusksInfo
- Publication number
- EP0792098A1 EP0792098A1 EP95940687A EP95940687A EP0792098A1 EP 0792098 A1 EP0792098 A1 EP 0792098A1 EP 95940687 A EP95940687 A EP 95940687A EP 95940687 A EP95940687 A EP 95940687A EP 0792098 A1 EP0792098 A1 EP 0792098A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- mollusk
- pinctada
- enhancing agent
- acceptor
- growth
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 241000237852 Mollusca Species 0.000 title claims abstract description 243
- 230000012010 growth Effects 0.000 title claims abstract description 162
- 230000002708 enhancing effect Effects 0.000 title claims abstract description 126
- 238000004519 manufacturing process Methods 0.000 title description 14
- 239000011049 pearl Substances 0.000 claims abstract description 100
- 238000000034 method Methods 0.000 claims abstract description 77
- 238000012258 culturing Methods 0.000 claims abstract description 51
- 230000009261 transgenic effect Effects 0.000 claims abstract description 33
- 239000003795 chemical substances by application Substances 0.000 claims description 109
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 34
- 150000007523 nucleic acids Chemical group 0.000 claims description 34
- 239000000203 mixture Substances 0.000 claims description 25
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 22
- 241000490567 Pinctada Species 0.000 claims description 22
- 102000004877 Insulin Human genes 0.000 claims description 21
- 108090001061 Insulin Proteins 0.000 claims description 21
- 229940125396 insulin Drugs 0.000 claims description 16
- 239000000122 growth hormone Substances 0.000 claims description 15
- 241001490476 Pinctada maxima Species 0.000 claims description 13
- 101710190529 Insulin-like peptide Proteins 0.000 claims description 10
- 210000004602 germ cell Anatomy 0.000 claims description 10
- 241000237890 Haliotis Species 0.000 claims description 9
- 238000013270 controlled release Methods 0.000 claims description 9
- 108010051696 Growth Hormone Proteins 0.000 claims description 8
- 241001287982 Pinctada albina Species 0.000 claims description 8
- 241000490568 Pinctada fucata Species 0.000 claims description 8
- 241001072293 Pinctada maculata Species 0.000 claims description 8
- 241001212699 Pinctada martensii Species 0.000 claims description 8
- 241000171541 Pinctada radiata Species 0.000 claims description 8
- 241000183300 Pteria penguin Species 0.000 claims description 7
- 238000003306 harvesting Methods 0.000 claims description 6
- 101000969137 Mus musculus Metallothionein-1 Proteins 0.000 claims description 5
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 claims description 2
- 102100038803 Somatotropin Human genes 0.000 claims 6
- 102000014429 Insulin-like growth factor Human genes 0.000 claims 1
- 241000237502 Ostreidae Species 0.000 description 76
- 235000020636 oyster Nutrition 0.000 description 73
- 210000001519 tissue Anatomy 0.000 description 46
- 230000008569 process Effects 0.000 description 19
- 238000011282 treatment Methods 0.000 description 15
- 239000000243 solution Substances 0.000 description 14
- 108700019146 Transgenes Proteins 0.000 description 12
- 210000004027 cell Anatomy 0.000 description 12
- 230000000366 juvenile effect Effects 0.000 description 12
- 235000013601 eggs Nutrition 0.000 description 10
- 230000001965 increasing effect Effects 0.000 description 10
- 238000002347 injection Methods 0.000 description 9
- 239000007924 injection Substances 0.000 description 9
- 108020004414 DNA Proteins 0.000 description 8
- 241000894007 species Species 0.000 description 8
- 108091026890 Coding region Proteins 0.000 description 7
- 230000002710 gonadal effect Effects 0.000 description 7
- 238000002513 implantation Methods 0.000 description 7
- 230000001418 larval effect Effects 0.000 description 7
- 108020004707 nucleic acids Proteins 0.000 description 7
- 102000039446 nucleic acids Human genes 0.000 description 7
- 108091029865 Exogenous DNA Proteins 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 239000004026 insulin derivative Substances 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 239000000523 sample Substances 0.000 description 6
- 239000013535 sea water Substances 0.000 description 6
- 241000283690 Bos taurus Species 0.000 description 5
- 238000001574 biopsy Methods 0.000 description 5
- 238000007654 immersion Methods 0.000 description 5
- PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 description 5
- 102000004196 processed proteins & peptides Human genes 0.000 description 5
- 108090000765 processed proteins & peptides Proteins 0.000 description 5
- 230000003442 weekly effect Effects 0.000 description 5
- 101000976075 Homo sapiens Insulin Proteins 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 239000002299 complementary DNA Substances 0.000 description 4
- 238000004520 electroporation Methods 0.000 description 4
- 238000010348 incorporation Methods 0.000 description 4
- 238000003780 insertion Methods 0.000 description 4
- 230000037431 insertion Effects 0.000 description 4
- 239000011159 matrix material Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 241000251468 Actinopterygii Species 0.000 description 3
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 3
- 108010005991 Pork Regular Insulin Proteins 0.000 description 3
- 108010076504 Protein Sorting Signals Proteins 0.000 description 3
- 239000003623 enhancer Substances 0.000 description 3
- 235000019688 fish Nutrition 0.000 description 3
- 230000029052 metamorphosis Effects 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 102000007469 Actins Human genes 0.000 description 2
- 108010085238 Actins Proteins 0.000 description 2
- 101001011741 Bos taurus Insulin Proteins 0.000 description 2
- 241000237504 Crassostrea virginica Species 0.000 description 2
- 102000018997 Growth Hormone Human genes 0.000 description 2
- 108091026898 Leader sequence (mRNA) Proteins 0.000 description 2
- 241000237536 Mytilus edulis Species 0.000 description 2
- 241000277275 Oncorhynchus mykiss Species 0.000 description 2
- 241000714474 Rous sarcoma virus Species 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- IXIBAKNTJSCKJM-BUBXBXGNSA-N bovine insulin Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 IXIBAKNTJSCKJM-BUBXBXGNSA-N 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 230000008021 deposition Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 210000000981 epithelium Anatomy 0.000 description 2
- 239000010437 gem Substances 0.000 description 2
- 229910001751 gemstone Inorganic materials 0.000 description 2
- 210000002149 gonad Anatomy 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 239000000411 inducer Substances 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 235000020638 mussel Nutrition 0.000 description 2
- 239000011050 natural pearl Substances 0.000 description 2
- 230000008488 polyadenylation Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 230000003134 recirculating effect Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- DIGQNXIGRZPYDK-WKSCXVIASA-N (2R)-6-amino-2-[[2-[[(2S)-2-[[2-[[(2R)-2-[[(2S)-2-[[(2R,3S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S,3S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2R)-2-[[2-[[2-[[2-[(2-amino-1-hydroxyethylidene)amino]-3-carboxy-1-hydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1,5-dihydroxy-5-iminopentylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]hexanoic acid Chemical compound C[C@@H]([C@@H](C(=N[C@@H](CS)C(=N[C@@H](C)C(=N[C@@H](CO)C(=NCC(=N[C@@H](CCC(=N)O)C(=NC(CS)C(=N[C@H]([C@H](C)O)C(=N[C@H](CS)C(=N[C@H](CO)C(=NCC(=N[C@H](CS)C(=NCC(=N[C@H](CCCCN)C(=O)O)O)O)O)O)O)O)O)O)O)O)O)O)O)N=C([C@H](CS)N=C([C@H](CO)N=C([C@H](CO)N=C([C@H](C)N=C(CN=C([C@H](CO)N=C([C@H](CS)N=C(CN=C(C(CS)N=C(C(CC(=O)O)N=C(CN)O)O)O)O)O)O)O)O)O)O)O)O DIGQNXIGRZPYDK-WKSCXVIASA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 206010069754 Acquired gene mutation Diseases 0.000 description 1
- 241000206761 Bacillariophyta Species 0.000 description 1
- 241000237519 Bivalvia Species 0.000 description 1
- 241000195493 Cryptophyta Species 0.000 description 1
- 101150074155 DHFR gene Proteins 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
- 108010000521 Human Growth Hormone Proteins 0.000 description 1
- 102000002265 Human Growth Hormone Human genes 0.000 description 1
- 239000000854 Human Growth Hormone Substances 0.000 description 1
- 241001501885 Isochrysis Species 0.000 description 1
- 241001501873 Isochrysis galbana Species 0.000 description 1
- 108090000157 Metallothionein Proteins 0.000 description 1
- 102000003792 Metallothionein Human genes 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000277338 Oncorhynchus kisutch Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 102000013275 Somatomedins Human genes 0.000 description 1
- 108091036066 Three prime untranslated region Proteins 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 238000012382 advanced drug delivery Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 150000001413 amino acids Chemical group 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000009360 aquaculture Methods 0.000 description 1
- 244000144974 aquaculture Species 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- VQLYBLABXAHUDN-UHFFFAOYSA-N bis(4-fluorophenyl)-methyl-(1,2,4-triazol-1-ylmethyl)silane;methyl n-(1h-benzimidazol-2-yl)carbamate Chemical compound C1=CC=C2NC(NC(=O)OC)=NC2=C1.C=1C=C(F)C=CC=1[Si](C=1C=CC(F)=CC=1)(C)CN1C=NC=N1 VQLYBLABXAHUDN-UHFFFAOYSA-N 0.000 description 1
- 108010006025 bovine growth hormone Proteins 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 241001233037 catfish Species 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000013611 chromosomal DNA Substances 0.000 description 1
- 235000020639 clam Nutrition 0.000 description 1
- 239000010984 cultured pearl Substances 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000005553 drilling Methods 0.000 description 1
- 210000002308 embryonic cell Anatomy 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000004720 fertilization Effects 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000013505 freshwater Substances 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 239000007952 growth promoter Substances 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000000050 nutritive effect Effects 0.000 description 1
- 230000005789 organism growth Effects 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 238000004064 recycling Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 210000001082 somatic cell Anatomy 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
- 230000037439 somatic mutation Effects 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 238000011179 visual inspection Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K61/00—Culture of aquatic animals
- A01K61/50—Culture of aquatic animals of shellfish
- A01K61/54—Culture of aquatic animals of shellfish of bivalves, e.g. oysters or mussels
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A40/00—Adaptation technologies in agriculture, forestry, livestock or agroalimentary production
- Y02A40/80—Adaptation technologies in agriculture, forestry, livestock or agroalimentary production in fisheries management
- Y02A40/81—Aquaculture, e.g. of fish
Definitions
- the present invention generally relates to methods of enhancing the growth of pearl-producing mollusks through the exposure of the mollusks to growth enhancing agents. Also provided are transgenic mollusks capable of expression of exogenous growth enhancing agents, and methods of culturing pearls.
- the pearl has long been considered a prized jewel valued for both its lustre and brilliance.
- the pearl is a product of animal origin, being produced by mollusks.
- a pearl is generally formed when a foreign body becomes embedded in the tissue of a mollusk. Unable to dislodge the foreign body, the mollusk coats it with a calcium carbonate composition which is secreted from its epithelial, or "mantle” tissues.
- J . Taburiaux, Pearls Their Origin Treatment and Identification , (D. Ceriog-Hughes, Trans., Chilton Book Co., 1986). This secreted material is termed the "nacre.” After a prolonged period, the foreign body is encased in the nacre and has become what is commonly known as a pearl.
- pearl oysters Modern commercial pearl culturing is practiced using several species of pearl oysters and other mollusks, including abalone, clams and mussels.
- the pearl oysters are collected from the wild as adults, caught in the wild as juveniles, or "spat", in spat collectors, or can be produced in hatcheries by spawning broodstocks. The oysters are then raised for use in the production of pearls.
- spat or juvenile oysters also described as pre-adult oysters, require culturing of at least one year before they reach adult size and are large enough to be used for pearl production.
- a foreign body In the typical pearl culturing process, a foreign body, or "nucleus,” is implanted into the gonadal tissue of a mollusk, typically an oyster species. Where "mabe" pearls are being produced, this nucleus is attached directly to the shell of the mollusk, directly contacting the mantle tissue of the acceptor mollusk.
- the mantle is a fold of epithelial tissue which surrounds the collection of organs and tissue between the shells, or valves, of the oyster. These organs and the mantle are herein referred to collectively as the "body” of the mollusk.
- the outer portion of this mantle is generally responsible for periostracum formation and nacre production.
- a small piece of mantle tissue from a separate, or "donor” mollusk is implanted in the mollusk concurrently with the implantation of the nucleus.
- the mollusk into which the nucleus and, optionally, the donor tissue is implanted is generally termed the "acceptor" shell or mollusk. Without being bound to any theory, it is believed that the donor mantle tissue surrounds the nucleus as the
- pearl sac and secretes the nacre which forms the pearl, while the acceptor mollusk acts as a nutritive repository for the process. See, Taburiaux, supra.
- the time from implantation of the nucleus to harvesting of the pearls can take from eighteen months to three years.
- growth regulating hormones including those of mammalian origin, such as insulin and growth hormone, have been reported to be effective in accelerating the growth rate of post-larval abalone. See, Morse, Aquaculture , 39:263-282 (1984).
- the present invention provides methods of enhancing the growth rates of pearl-producing mollusks, and also provides mollusks having enhanced growth rates. Increased growth rates lessen the time required for spat to be cultured prior to their use in pearl production. Additionally, an increase in the growth rate of a pearl producing mollusk results in an increase in the rate of nacre production around implanted nuclei, thus reducing the culturing time for the pearl. Such a decrease in culturing time also increases the number of mollusks that can be recultured, further reducing costs. Therefore, the yield of pearl producers is increased through faster preculturing and culturing processes, recycling of pearl mollusks and reduced flaws in the pearls produced. Further, the potential size of the pearls produced is also be increased.
- One embodiment of the present invention provides a method of enhancing the growth of a pearl producing mollusk.
- the method comprises introducing into the germline of the mollusk a nucleic acid sequence, which comprises a segment encoding a growth enhancing agent operably linked to a promoter sequence whereby the segment is capable of expressing the growth enhancing agent in the mollusk.
- the present invention also provides a transgenic mollusk wherein the mollusk's germline comprises an exogenous nucleic acid sequence.
- This exogenous nucleic acid sequence comprises a segment which encodes a growth enhancing agent, and is capable of expressing the growth enhancing agent in the mollusk.
- the present invention also provides a method of culturing pearls.
- This method comprises the steps of introducing a nucleus into an acceptor mollusk.
- the method may comprise the concurrent introduction of mantle tissue from a donor mollusk into the acceptor mollusk.
- the acceptor mollusk is exposed to an effective amount of a growth enhancing agent and cultured.
- pearls are harvested from the acceptor mollusk.
- the acceptor mollusk is exposed to the growth enhancing agent by immersing the acceptor mollusk in a solution comprising the growth enhancing agent at a concentration of from about 1 nM to about 10 mM of the growth enhancing agent, and more preferably, at a concentration of from about 0.1 ⁇ M to about 100 ⁇ M of the growth enhancing agent. Such exposure is generally carried out from about monthly to weekly to about daily.
- the acceptor mollusk is exposed to the growth enhancing agent by inserting a composition comprising the growth enhancing agent into the interior of the acceptor mollusk. Insertion of the composition comprising the growth enhancing agent is carried out, for example, by injecting the composition into the interior of the mollusk, or by manually placing the composition in the interior of the mollusk.
- Such compositions optionally comprise the growth enhancing agent free in solution or incorporated in a matrix, such as a controlled release composition whereby a constant low-level release of the growth enhancing agent occurs.
- the present invention also provides a method of culturing pearls comprising the steps of introducing into an acceptor mollusk, a nucleus and mantle tissue from a donor mollusk, where the donor mollusk comprises an exogenous nucleic acid sequence which encodes a growth enhancing agent, said sequence being operably linked to a promoter sequence whereby said mantle tissue from said donor is capable of expressing said growth enhancing agent.
- the acceptor mollusk is then cultured. Following this culturing, pearls are harvested from the acceptor mollusk.
- the present invention provides a method of culturing pearls comprising the steps of introducing a nucleus into an acceptor mollusk, and optionally comprising concurrently introducing mantle tissue from a donor mollusk into said acceptor mollusk, said acceptor mollusk comprising an exogenous nucleic acid sequence which encodes a growth enhancing agent, said sequence being operably linked to a promoter sequence whereby the acceptor mollusk is capable of expressing the growth enhancing agent; culturing said acceptor mollusk; and harvesting pearls from said acceptor mollusk.
- the present invention provides a method for culturing pearls comprising exposing a mollusk to an effective amount of a growth enhancing agent prior to the introduction of a nucleus and optionally the donor mantle tissue. Following introduction of the nucleus, and optionally, the mantle tissue from a donor mollusk, into the interior of the acceptor mollusk, the acceptor mollusk is cultured, and pearls are harvested therefrom.
- the mollusk is a juvenile, larval or embryonic mollusk.
- the growth enhancing agent is preferably selected from the group consisting of insulins, insulin-like growth factors and growth hormones. More preferably, the growth enhancing agent is porcine, bovine or human growth hormone or insulin. Most preferably, the growth enhancing agent is porcine, bovine or human insulin.
- preferred promoter sequences are selected from the group consisting of RSV-LTR, actin and metallothionein promoter sequences.
- the preferred mollusks of the embodiments of the present invention are selected from the group consisting of Pinctada maxima, Pinctada mar ger it if era, Pinctada martensi fucata, Pinctada radiata, Pinctada vulgaris, Pinctada fucata, Pinctada maculata, Pinctada albina , Pteria penguin , Unionides sp. and Haliotis sp.
- such mollusks are selected independently from this group.
- An object of the present invention is to provide methods of enhancing the growth of pearl producing mollusks as well as provide mollusks having such enhanced growth characteristics. These methods and mollusks are useful in the pearl culturing process to reduce processing time and increase size and number yields of pearl producing mollusks.
- Mollusks which are particularly useful in the present invention include oyster species such as Pteria penguin, Pinctada maxima, Pinctada mar ger it if era, Pinctada martensi fucata, Pinctada radiata, Pinctada vulgaris, Pinctada fucata, Pinctada albina and Pinctada maculata .
- Other pearl-producing mollusks including abalone, from the Haliotis genus and fresh water mussels of the Unionides genus. See Taburiaux, supra.
- the term mollusk is used generically to include adult mollusks, as well as juvenile, larval and embryonic forms thereof.
- Mollusks having enhanced growth characteristics generally show an increase in one or more of the following characteristics compared with mollusks having normal growth characteristics: shell height, shell length, overall weight or tissue mass.
- An enhanced growth rate for a mollusk is the change in mass, length or height per unit time of about 1-150, 10-100 or 20-50% greater than that of a normal mollusk of similar size and age in a similar environment. For example, a normal oyster exhibiting an increase in shell length of lOmm/month, would have that rate of increase enhanced to from about 10.1 mm/month to about 25 mm/month.
- mollusks whose growth rate is enhanced also have increased periostracum formation and shell deposition over those mollusks without an enhanced growth rate. Such increased periostracum formation and shell deposition also increase the rate of nacre production which results in an increase in the rate of pearl formation. Additionally, mollusks having an enhanced growth rate, having achieved a larger size, are capable of harboring larger nuclei and/or pearls within their interior.
- pearls produced by a mollusk whose growth rate is enhanced or within tissue capable of expressing a growth enhancing agent according to the methods of the present invention generally have a diameter of from about 5 % to about 50 % greater than pearls formed by a mollusk whose growth rate is not enhanced, when cultured under similar conditions for a similar time period.
- a pearl cultured in a nonenhanced growth mollusk is about 10 mm in diameter
- a pearl cultured in a mollusk having an enhanced growth rate over the same period is from about 10.5 to about 15 mm in diameter.
- the mollusk having the enhanced growth rate produces a pearl of given diameter in diameter in about 5-30% less time than a mollusk having a normal growth rate.
- Growth enhancing agents generally include those compounds which when exposed to living organisms, directly or indirectly induce the growth of the organism, thereby increasing the organism's growth rate over and above the natural growth rate of that organism.
- compounds essential to the existence of the organism i.e. nutrients, oxygen or water, are not included within the definition of growth enhancing agents.
- growth enhancing agents include growth hormones, growth factors, insulins and insulin-like peptides.
- growth enhancing agents include those factors which induce the release of natural growth inducers within the mollusk. These endocrinological "triggers" result in increased expression of the mollusk's natural growth inducers, thus resulting in an enhanced growth rate. These triggers of growth related hormones have been described in other vertebrates.
- Specific growth hormones which are useful in the present invention include fish growth hormones, i.e., rainbow trout (Agellon and Chen, DNA 5:463-471 (1986)), coho salmon (Villasenor, et al, Gene 65:239-246), and catfish (Tang, et al., Mol . Mar. Biol . and Biotech . , 2(4) :198-206) , as well as bovine, porcine and human growth hormones.
- insulins which are particularly useful in the present invention include mammalian insulins, such as porcine, bovine and human insulin. See, e.g., Plisetskaya, et al., Gen . Comp . Endocrin .
- Insulin-like peptides such as human and molluscan insulin-like peptides ("MIP") , are also useful as growth enhancing agents in the methods and mollusks of the present invention. See, e.g., Smit, et al., J. Mol . Endocrin . , 11:103-113 (1993), Smit, et al., Mol . Brain Research , 14:7-12 (1992). Also included are analogs or amino acid sequence variants of these agents.
- MIP molluscan insulin-like peptides
- the invention provides methods for enhancing the growth rate of a mollusk and a mollusk having an enhanced growth rate.
- the mollusks are produced and the methods are practiced by introducing into the mollusk an exogenous nucleic acid sequence which comprises a segment which encodes a growth enhancing agent operably linked to a promoter sequence, whereby the mollusk is capable of expressing the growth enhancing agent.
- a DNA segment is operably linked when placed into a functional relationship with another DNA segment.
- a promoter or enhancer is operably linked to a coding sequence if it stimulates the transcription of the sequence;
- DNA for a signal sequence is operably linked to DNA encoding a polypeptide if it is expressed as a preprotein that participates in the secretion of the polypeptide.
- DNA sequences that are operably linked are contiguous, and in the case of a signal sequence both contiguous and in reading phase.
- enhancers need not be contiguous with the coding sequences whose transcription they control. Linking is accomplished by ligation at convenient restriction sites or at adapters or linkers inserted in lieu thereof.
- exogenous DNA segment is one foreign to the cell, or homologous to the cell, but in a position within the host cell genome in which the element is not ordinarily found.
- exogenous DNA segments include heterologous nucleic acid sequences derived from species, genera, families and the like, other than the organism into which it is introduced.
- Exogenous DNA segments also include a homologous coding sequence operably linked to a heterologous promoter sequence, or alternatively, a heterologous coding sequence operably linked to a homologous promoter sequence.
- Exogenous DNA segments further include a multiple gene copy nucleic acid sequence where such is not present in the native genome. The presence of multiple copies can result in increased production of the growth enhancing agent relative to expression in the native genome.
- Exogenous DNA segments are expressed to yield exogenous polypeptides.
- the nucleic acid sequence encoding the growth enhancing agent is selected from the group of nucleic acids which encode growth hormones, insulins and insulin-like peptides.
- the nucleic acid sequences for a variety of growth hormones have been reported. See, e.g. , Agellon and Chen, DNA 5:463-471 (1986), Villasenor, et al, Gene 65:239-246, and Tang, et al., Mol . Mar. Biol . And Biotech . , 2(4) :198-206.
- the nucleic acid sequences for insulin related peptides, and specifically for Human and Molluscan Insulin-like Peptide, have also been reported.
- nucleic acid sequences for various insulins e.g., human, porcine and bovine, have been reported and are also available from GenBank.
- Other nucleic acids encoding growth enhancing agents of the present invention can be synthesized, or directly cloned from genomic libraries using, for example, PCR methods. See, e.g., Alberts, et al.. Molecular Biology of the Cell (2nd Ed.
- the nucleic acid sequence encoding the growth enhancing agent can be genomic, cDNA, minigene (i.e., genomic without selected intronic regions not required for expression) or a hybrid of any of these.
- the desired sequence is coupled to an appropriate promoter sequence.
- Promoter sequences useful in the present invention include those of prokaryotic or eucaryotic origin. Generally, promoters that are functional in mammalian cells are also functional in lower eucaryotic forms such as fish or mollusks.
- Preferred promoter sequences are the long terminal repeat sequence of the Avian Rous Sarcoma Virus (RSV-LTR) (see, e.g., Chen, et al., Mol . Marine Biol . and Biotech . , 2(2):88-95 (1993), Dunham, et al., Mol . Marine Biol . and Biotech . , 1(4/5) :380-389 (1992)), the inducible mouse metallothionein-I promoter, as well as the actin, pgk , tk, and dhfr promoters.
- RSV-LTR Avian Rous Sarcoma Virus
- the coding sequence is operably linked to additional control sequences, such as an enhancer, a 3' and/or 5' untranslated region, a 3' and/or 5 1 flanking region, an intronic sequence, a signal sequence capable of directing secretion of the growth promoting factor from the cell in which it is expressed, and a polyadenylation site.
- additional control sequences such as an enhancer, a 3' and/or 5' untranslated region, a 3' and/or 5 1 flanking region, an intronic sequence, a signal sequence capable of directing secretion of the growth promoting factor from the cell in which it is expressed, and a polyadenylation site.
- Additional regulatory sequences are often obtained from sequences naturally flanking the coding sequence of the growth promoting factor and/or the promoter.
- the sequence encoding the growth enhancing agent is fused in-frame to a second exogenous protein-coding sequence, such that the growth enhancing agent is expressed as a fusion protein.
- the presence of all or part of the second exogenous protein can enhance or facilitate the targeting, stability, acceptance and/or processing of the growth enhancing agent within the cells of the mollusk.
- Nucleic acid sequences are introduced into the germline of a mollusk embryo to generate a transgenic mollusk.
- a transgenic mollusk is one in which all of the somatic and germline cells (with the possible exception of a few cells subject to somatic mutation) contain at least one copy of an integrated transgene, the transgene having been introduced into the germline of the mollusk or an ancestor of the mollusk at an early embryonic stage.
- the nucleic acid can be introduced into individual mollusk embryos at the one- cell (i.e., zygote) or two-cell stage. Introducing DNA at the one-cell stage results in a higher probability of germline incorporation. Incorporation at later stages often results in a mosaic mollusk, only some of whose cells have integrated the transgene.
- nucleic acids encoding growth enhancing agents can be introduced into mollusks using the same procedure as described for introducing such nucleic acids into t-ransgenic fish. See, e.g., Dunham, et al., supra, Chen, et al., supra.
- the exogenous nucleic acid segment is introduced into the mollusk by electroporation of a fertilized mollusk egg.
- the presence of an integrated transgene in the genome of a mollusk is confirmed by extracting DNA from a tissue biopsy and analyzing the DNA for the presence of the nucleic acid sequence, e.g., by Southern analysis of DNA using probes specific for the exogenous nucleic acid sequence of the growth enhancing agent. Expression of the transgene is confirmed by Northern analysis of RNA from the biopsy using a similar probe. Alternatively, a protein extract of the biopsy is analyzed by Western blotting, radioimmunoassay or ELISA using an antibody to the growth enhancing factor being expressed as the probe. True transgenic status is established by transmission of the transgene from PI mollusks to FI progeny.
- the PI mollusks can be bred either with other PI mollusks or with nontransgenic mollusks. Interbreeding of transgenic mollusks can be used to establish a mollusk line that is homozygous for the integrated transgene.
- the invention provides methods for culturing pearls by enhancing the growth of the mollusks involved in the pearl culturing process.
- a foreign body, or "nucleus” is introduced or implanted into the gonadal tissue of a mollusk.
- the mollusk receiving this nucleus is termed the mother or acceptor mollusk.
- Nuclei include any foreign body around which the mollusk produces a nacre. Such nuclei are generally small rounded objects, such as fragments of shells from other mollusks, metallic spheres, or other similarly shaped objects. The size and shape of such nuclei depends upon the size and shape of the pearl desired.
- the invention provides custom shaped nuclei for producing pearls of any desired shape.
- a piece of tissue from the mantle portion of a mollusk is also implanted in the gonadal tissue of the acceptor mollusk along with the nucleus.
- the mollusk from which this mantle tissue is derived is termed the "donor" mollusk.
- the mantle tissue is taken from a separate donor mollusk
- the mantle tissue can be derived from the acceptor mollusk and reimplanted along with the nucleus in the gonadal tissue of that acceptor mollusk.
- the acceptor mollusk can also be the donor mollusk.
- the acceptor mollusk and the donor mollusk are the same species, this need not be the case.
- the implantation of the nucleus and donor mantle tissue is carried out by conventional methods routine in pearl culturing processes.
- a nucleus can be implanted between the shell and mantle of the acceptor mollusk, e.g. , in the production of mabe pearls. Where this is the case, the implantation of the donor mantle tissue can be omitted.
- One embodiment of the present invention provides a method for culturing pearls comprising exposing pre-adult mollusks, e.g., juvenile, spat or larval mollusks, to an effective amount of a growth enhancing agent, whereby the growth rate of the mollusk is enhanced.
- a nucleus and optionally, mantle tissue from a donor mollusk is introduced into the mollusk.
- the mollusk is then cultured and pearls are harvested therefrom.
- Whether a mollusk has reached adult size is dependent upon industry standards for a particular pearl producing mollusk, and as a result, varies from species to species. For example, the larger species of Haliotis have a larger adult size than the more typical Pinctada maxima oyster species.
- the raising of mollusk spat for use in pearl culturing processes can take upwards of 24 months.
- the present invention expedites the preculturing aspect of pearl culturing by enhancing the growth rate of juvenile or larval mollusks.
- the exposing of mollusk spat to an effective amount of growth enhancing agent can comprise immersing the spat in a solution comprising growth enhancing agent at a concentration of from about 1 X 10 ⁇ 9 M (InM) to about 1 X 10" 2 M (lOmM) .
- immersion treatments should preferably comprise immersing the spat in the composition comprising the growth enhancing agent for from about 30 minutes to about 10 hours, and can be carried out as frequently as necessary to achieve the desired results.
- such treatments are carried out daily, semi-weekly, weekly, biweekly or monthly during a portion of, or throughout the preculturing process.
- the present invention provides a method of culturing pearls comprising the steps of introducing into an acceptor mollusk, a nucleus and, optionally, mantle tissue from a donor mollusk, and exposing the acceptor mollusk to an effective amount of a growth enhancing agent.
- the acceptor mollusk is then cultured, and pearls are harvested therefrom.
- the nucleus is implanted between the oyster shell and the mantle of the acceptor mollusk
- the implantation of mantle tissue from the donor mollusk can be omitted.
- the exposing of the acceptor mollusk to the growth enhancing agent may take a variety of forms.
- the implanted acceptor mollusk to be exposed to the growth enhancing agent is immersed in a solution which comprises an effective amount of the growth enhancing agent.
- This immersion treatment is carried out in substantially the same fashion as the treatment described for juvenile or larval oysters. Again, these treatments are preferably carried out daily, semi-weekly, weekly, biweekly or monthly during a portion of, or throughout the pearl culturing process. More preferably, the treatments are carried out during the natural growing season of the mollusk.
- the solution comprising an effective amount of the growth enhancing agent described above is manually introduced between the valves of the implanted acceptor mollusk.
- the solution comprising the growth enhancing agent as described above is directly injected into the body or pallial space of the mollusk. While these injections are generally carried out on an implanted acceptor mollusk, these injections may be performed prior to implantation.
- injections can be carried out by a number of methods, i.e., inserting a syringe needle between the opposing valves of the acceptor mollusk (a natural gap exists between valves in some oyster species, i.e., Pinctada maxima) , filing a notch to produce a small hole in the junction of the two valves, or drilling a small hole in a valve so as to allow the injection of growth enhancing agent between the valves.
- the solution comprising the growth enhancing agent is injected in a volume of from about 0.5 to about 2.0 mL.
- the injection is into the pallial or extrapallial spaces of the mollusk so as not to penetrate the organs or tissue which comprise the body of the mollusk.
- the injection treatments are carried out daily, semi-weekly, weekly, biweekly or monthly.
- Effective amounts of growth enhancing agents in the above described solutions vary with the particular growth enhancing agent used. In general, effective amount is defined as a combination of concentration of growth enhancing agent in the solution to which the mollusk is exposed, the length of the individual exposure treatments and number and frequency of exposure treatments.
- the growth enhancing agents are usually present in the above described solutions at a concentration of about 1 X 10 "9 M (lnM) to about 1 X 10 "2 M (lOmM) . More preferred are solutions wherein the growth enhancing agent is present in a concentration of from about 1 X 10 "6 M (1 ⁇ M) to about 1 X 10 " 4 M (100 ⁇ M) .
- the growth enhancing agent is dispersed in seawater or other appropriate saline solutions.
- the present invention also provides for the insertion of a controlled release composition comprising a growth enhancing agent in the tissue of the implanted acceptor mollusk.
- Controlled release compositions are generally in the form of a tablet, capsule or liposome such that the composition is retained within the tissue of the mollusk while releasing a constant low level of the growth enhancing agent.
- These controlled release compositions generally incorporate the growth enhancing agent in a matrix such that the composition can release effective amounts of the growth enhancing agent over a sustained period of time.
- the growth enhancing agents are contained within beads, capsules, or microcapsules, surrounded by a barrier which degrades slowly over time to sustain a constant, low level release of the growth enhancing agent into the surrounding environment, without producing degradation products harmful to the mollusk.
- Compositions useful as barriers are generally commercially available and include, for example, those compositions which are generally used in pharmaceutical applications. See Heller et al., Advanced Drug Delivery Rev . 10:163-204 (1993) and Tyrrell et al., Biochim . Biophys . Acta 457:259-302 (1976).
- the growth enhancing agents can also be adsorbed to a matrix whereby the growth enhancing agent is slowly released from the matrix in the culturing environment.
- the controlled release compositions are inserted into the body or tissue of the acceptor mollusk.
- the controlled release composition can be inserted directly into the gonadal tissue of the mollusk so as to create a region of higher concentration of the growth enhancing agent in the immediate area of pearl formation.
- the slow dissolving nature of these controlled release compositions prevents them from acting as a nucleus for nacre formation.
- pearls are harvested from the acceptor mollusks by conventional methods. These mollusks can then be reimplanted for repeated pearl culturing, if desired.
- the modern pearl culturing process generally comprises the implantation or insertion of a nucleus and a piece of mantle tissue into the gonadal tissue of the acceptor mollusk.
- this process may vary, for example, where mabe pearls are desired.
- the nucleus and mantle tissue from a donor mollusk are implanted into a transgenic acceptor mollusk.
- the transgenic acceptor mollusk comprises an exogenous nucleic acid sequence which comprises a segment encoding a growth enhancing agent operably linked to a promoter sequence.
- the transgenic acceptor mollusk is thereby capable of expressing the growth enhancing agent.
- the mantle tissue which is implanted into the acceptor mollusk is obtained from a transgenic donor mollusk.
- the donor mollusk then comprises the exogenous nucleic acid sequence comprising a segment encoding a growth enhancing agent operably linked to a promoter sequence.
- the implanted cells from the donor mollusk are thus capable of expressing the growth enhancing agent.
- This particular embodiment is particularly useful where it is desirable to avoid releasing a transgenic mollusk species into the environment. Therefore, this embodiment is readily be practiced on the scale of a commercial pearl culturing operation.
- either or both the acceptor and donor mollusks can be transgenic, i.e., capable of expressing an exogenous growth enhancing agent.
- oysters at various stages of development are used. Accordingly, the initial example describes the raising and culturing of oysters from egg cells to adult oysters.
- Typical broodstock oysters are collected from the wild just prior to the natural spawning season. These oysters are kept in flow through or recirculating seawater at temperatures just below the natural spawning temperature. These are typically from about 25 to about 30°C. When judged to be in spawning condition by visual inspection of the gonads, the temperature is increased by from about 5°C to about 8°C. This temperature increase usually induces spawning.
- oysters Upon induction of spawning, oysters are identified as male or female and placed in separate vessels accordingly.
- the oysters When spawning is complete, the oysters are removed from their respective tanks, and the sperm and egg suspensions are collected and mixed. Once fertilized, the eggs are transferred to another tank to begin the larval culture. Fertilized eggs are stocked at a density of from about 20 to about 30 eggs per ml and kept in aerated tanks for 24 to 48 hours, during which time the eggs hatch. The larvae from the eggs are collected on sieves and placed in tanks at a density of about 20 larvae per ml, and fed algae. The feed is typically a mixture of diatoms and Isochrysis galbana , at a density of 20,000 to 30,000 cells/ml in the larval tanks.
- Metamorphosis may be chemically induced in some species.
- Juvenile pearl oysters (Pinctada margeritifera) approximately 1 mm in length, were obtained from a commercial source. These juveniles were maintained in closed recirculating aquaria at 28°C, and fed Thallasiosira and Isochrysis . A subset of the juveniles was immersed in seawater containing 10 "6 M insulin while another group was immersed in seawater alone. After one week, the treated group showed 30% greater growth than the untreated group. Continued weekly immersions resulted in continued accelerated growth of the juveniles over that of the untreated group. No mortality was observed in either group.
- a slow-release insulin capsule such as described by Heller, supra is inserted into the tissue or gonad of a test group of oysters. Concurrently with the insertion of the insulin capsule, a nucleus of 10 mm in diameter and a 25 mm 2 sample of mantle tissue from a donor oyster are inserted into a separate incision in the gonadal tissue of the test oyster. The oysters are closed and returned to normal culture conditions. After culturing for 12 months, the test oysters are opened and their pearls are harvested. Pearls harvested from these test oysters have a larger diameter and a greater dry weight than pearls produced by the control group.
- Example 4 Injection of the Growth Enhancing Agent Juvenile Pinctada maxima oysters are removed from their culture conditions. An 18-gauge needle is inserted through the dorsal notch into the pallial space of each oyster. One ml of lOO ⁇ M insulin solution is injected into the oyster. The injected oysters are held out of the water for one hour. After treatment, the oysters are returned to their normal culture conditions. The injections are repeated every 14 days during the growing season. After 12 months, the oysters show greater percent growth than the oysters of the control group.
- the cDNA sequence of human insulin has been described. See, Gen Bank Ace. No. L15440.
- the cDNA coding sequence including 3• and 5' untranslated regions and a polyadenylation signal is modified by the addition of Sail linkers and ligated to a Rous Sarcoma Virus long terminal repeat (RSV-LTR) promoter/enhancer sequence at the Sail site in a pRSV-2 vector, as described by Gorman et al, Proc. Natl Acad. Sci. (USA) 79:6777-6781 (1982).
- the cDNA coding sequence is thereby linked to 580 bp of the LTR sequence and 3.7 kb of pRSV flanking sequence.
- the vector After propagation of the vector, the vector is linearized to provide a transgene suitable for injection.
- the linearized transgene is electroporated into fertilized eggs from Pinctada maxima obtained from a commercial hatchery or by laboratory spawning and fertilization.
- the eggs are cultured to spat and juvenile oysters.
- the presence of the RSV-LTR-Insulin transgene is assayed from a biopsy of the oyster tissue.
- Chromosomal DNA is extracted and amplified using primers hybridizable to the transgene.
- the amplification product is detected by gel electrophoresis. Expression of human insulin is detected by Western blotting of a protein extract from the biopsy.
- transgenic oysters are interbred to generate transgenic progeny, whose transgenic status and expression is assayed using the same methods as described for the founder oysters.
- Juvenile transgenic oysters which express the human insulin sequence are cultured under the same conditions as a control group of normal oysters of approximately equal size and age. After culturing for 12 months, the transgenic oysters show a higher percent growth than the oysters of the control group.
- Set 1 comprises the oysters of Example 5 which demonstrate enhanced growth rates relative to the control group.
- Set 2 comprises "normal" Pinctada maxima oysters, i.e., nontransgenic oysters.
- the oysters are implanted with a spherical nucleus 10 mm in diameter, and a 25 mm 2 sample of donor mantle tissue.
- the following sets of acceptor oysters results:
- the acceptor oysters are cultured in a marine environment for 12 months.
- the pearls obtained from the oysters of groups 1, 2 and 3 are larger in diameter and have a greater dry weight than those produced by the control group.
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Environmental Sciences (AREA)
- Marine Sciences & Fisheries (AREA)
- Zoology (AREA)
- Animal Husbandry (AREA)
- Biodiversity & Conservation Biology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Farming Of Fish And Shellfish (AREA)
- Cosmetics (AREA)
Abstract
The invention generally relates to methods of enhancing the growth of pearl producing mollusks through the exposure of the mollusk to a growth enhancing agent. Also provided are transgenic mollusks capable of expression of exogenous growth enhancing agents, and methods of culturing pearls comprising the use of these methods and mollusks.
Description
ENHANCING GROWTH AND PEARL PRODUCTION IN MOLLUSKS
The present invention generally relates to methods of enhancing the growth of pearl-producing mollusks through the exposure of the mollusks to growth enhancing agents. Also provided are transgenic mollusks capable of expression of exogenous growth enhancing agents, and methods of culturing pearls.
BACKGROUND OF THE INVENTION The pearl has long been considered a prized jewel valued for both its lustre and brilliance. Despite its customary classification as a "gem," the pearl is a product of animal origin, being produced by mollusks. A pearl is generally formed when a foreign body becomes embedded in the tissue of a mollusk. Unable to dislodge the foreign body, the mollusk coats it with a calcium carbonate composition which is secreted from its epithelial, or "mantle" tissues. J . Taburiaux, Pearls : Their Origin Treatment and Identification , (D. Ceriog-Hughes, Trans., Chilton Book Co., 1986). This secreted material is termed the "nacre." After a prolonged period, the foreign body is encased in the nacre and has become what is commonly known as a pearl.
Because the production of "natural pearls" relies entirely upon the happenstance occurrence of the embedding of a foreign body into the epithelial tissue of an oyster, yields of such natural pearls on a per oyster basis are low. In response to a higher worldwide demand for pearls, oyster farmers began artificially introducing foreign bodies into the tissue of the oyster. Pearls resulting from this process are termed "cultured pearls." By culturing pearls, farmers could ensure that the oyster possessed all of the starting materials necessary to create a pearl. Furthermore, by utilizing a foreign body of a desired size and shape, farmers could, to
some extent, control the final product of the pearl culturing process. See, Taburiaux, supra.
Modern commercial pearl culturing is practiced using several species of pearl oysters and other mollusks, including abalone, clams and mussels. The pearl oysters are collected from the wild as adults, caught in the wild as juveniles, or "spat", in spat collectors, or can be produced in hatcheries by spawning broodstocks. The oysters are then raised for use in the production of pearls. Generally, spat or juvenile oysters, also described as pre-adult oysters, require culturing of at least one year before they reach adult size and are large enough to be used for pearl production.
In the typical pearl culturing process, a foreign body, or "nucleus," is implanted into the gonadal tissue of a mollusk, typically an oyster species. Where "mabe" pearls are being produced, this nucleus is attached directly to the shell of the mollusk, directly contacting the mantle tissue of the acceptor mollusk. The mantle is a fold of epithelial tissue which surrounds the collection of organs and tissue between the shells, or valves, of the oyster. These organs and the mantle are herein referred to collectively as the "body" of the mollusk. The outer portion of this mantle is generally responsible for periostracum formation and nacre production. In culturing traditional pearls, a small piece of mantle tissue from a separate, or "donor" mollusk is implanted in the mollusk concurrently with the implantation of the nucleus. The mollusk into which the nucleus and, optionally, the donor tissue is implanted is generally termed the "acceptor" shell or mollusk. Without being bound to any theory, it is believed that the donor mantle tissue surrounds the nucleus as the
"pearl sac" and secretes the nacre which forms the pearl, while the acceptor mollusk acts as a nutritive repository for the process. See, Taburiaux, supra.
The time from implantation of the nucleus to harvesting of the pearls can take from eighteen months to three years.
Aside from the costs associated with this lengthy process, the large amount of time required for pearl culturing also increases the risk that an oyster will not survive to complete
the process or that a flaw will be created in the forming pearl, such as the incorporation of off-colored matter, an alteration of pressure on the forming pearl or an aggregation of two forming pearls resulting in a change in the pearls' shape. This risk is further increased where larger pearls are desired. Such larger pearls naturally require larger mollusks and a longer culture time to form. Finally, because the price of pearl oysters is high, it is desirable to "recycle" these oysters for multiple pearl cultures. However, currently, only approximately one third of pearl oysters are recultured. See, TaJuriaux, supra. It is thus desirable to reduce the time requirements in spat production and culture, and in the pearl culturing processes.
Exposure of the eastern oyster, Crassostrea virginica , to a class of growth enhancing bioactive peptides has been reported to increase the growth rates of both juvenile and adult oysters. Paynter & Chen, Biol . Bull . 181: 459-462 (1991) . In particular, exogenous treatment of these oysters with rainbow trout growth hormone was reported to increase both shell height and tissue weight over those oysters in the control group.
Additionally, the use of growth regulating hormones, including those of mammalian origin, such as insulin and growth hormone, have been reported to be effective in accelerating the growth rate of post-larval abalone. See, Morse, Aquaculture , 39:263-282 (1984).
The present invention provides methods of enhancing the growth rates of pearl-producing mollusks, and also provides mollusks having enhanced growth rates. Increased growth rates lessen the time required for spat to be cultured prior to their use in pearl production. Additionally, an increase in the growth rate of a pearl producing mollusk results in an increase in the rate of nacre production around implanted nuclei, thus reducing the culturing time for the pearl. Such a decrease in culturing time also increases the number of mollusks that can be recultured, further reducing costs. Therefore, the yield of pearl producers is increased through faster preculturing and culturing processes, recycling of
pearl mollusks and reduced flaws in the pearls produced. Further, the potential size of the pearls produced is also be increased.
SUMMARY OF THE INVENTION
One embodiment of the present invention provides a method of enhancing the growth of a pearl producing mollusk. The method comprises introducing into the germline of the mollusk a nucleic acid sequence, which comprises a segment encoding a growth enhancing agent operably linked to a promoter sequence whereby the segment is capable of expressing the growth enhancing agent in the mollusk.
In an alternate embodiment, the present invention also provides a transgenic mollusk wherein the mollusk's germline comprises an exogenous nucleic acid sequence. This exogenous nucleic acid sequence comprises a segment which encodes a growth enhancing agent, and is capable of expressing the growth enhancing agent in the mollusk.
In an additional embodiment, the present invention also provides a method of culturing pearls. This method comprises the steps of introducing a nucleus into an acceptor mollusk. Optionally, the method may comprise the concurrent introduction of mantle tissue from a donor mollusk into the acceptor mollusk. The acceptor mollusk is exposed to an effective amount of a growth enhancing agent and cultured. Following culturing, pearls are harvested from the acceptor mollusk.
In preferred embodiments, the acceptor mollusk is exposed to the growth enhancing agent by immersing the acceptor mollusk in a solution comprising the growth enhancing agent at a concentration of from about 1 nM to about 10 mM of the growth enhancing agent, and more preferably, at a concentration of from about 0.1 μM to about 100 μM of the growth enhancing agent. Such exposure is generally carried out from about monthly to weekly to about daily.
In a related embodiment, the acceptor mollusk is exposed to the growth enhancing agent by inserting a composition comprising the growth enhancing agent into the interior of the
acceptor mollusk. Insertion of the composition comprising the growth enhancing agent is carried out, for example, by injecting the composition into the interior of the mollusk, or by manually placing the composition in the interior of the mollusk. Such compositions optionally comprise the growth enhancing agent free in solution or incorporated in a matrix, such as a controlled release composition whereby a constant low-level release of the growth enhancing agent occurs. In a further embodiment, the present invention also provides a method of culturing pearls comprising the steps of introducing into an acceptor mollusk, a nucleus and mantle tissue from a donor mollusk, where the donor mollusk comprises an exogenous nucleic acid sequence which encodes a growth enhancing agent, said sequence being operably linked to a promoter sequence whereby said mantle tissue from said donor is capable of expressing said growth enhancing agent. The acceptor mollusk is then cultured. Following this culturing, pearls are harvested from the acceptor mollusk.
Alternatively, in another embodiment, the present invention provides a method of culturing pearls comprising the steps of introducing a nucleus into an acceptor mollusk, and optionally comprising concurrently introducing mantle tissue from a donor mollusk into said acceptor mollusk, said acceptor mollusk comprising an exogenous nucleic acid sequence which encodes a growth enhancing agent, said sequence being operably linked to a promoter sequence whereby the acceptor mollusk is capable of expressing the growth enhancing agent; culturing said acceptor mollusk; and harvesting pearls from said acceptor mollusk. In still another embodiment, the present invention provides a method for culturing pearls comprising exposing a mollusk to an effective amount of a growth enhancing agent prior to the introduction of a nucleus and optionally the donor mantle tissue. Following introduction of the nucleus, and optionally, the mantle tissue from a donor mollusk, into the interior of the acceptor mollusk, the acceptor mollusk is cultured, and pearls are harvested therefrom. Preferably, at
the time of the exposure, the mollusk is a juvenile, larval or embryonic mollusk.
For the various embodiments of the present invention, the growth enhancing agent is preferably selected from the group consisting of insulins, insulin-like growth factors and growth hormones. More preferably, the growth enhancing agent is porcine, bovine or human growth hormone or insulin. Most preferably, the growth enhancing agent is porcine, bovine or human insulin. For those embodiments comprising an exogenous nucleic acid sequence operably linked to promoter sequences, preferred promoter sequences are selected from the group consisting of RSV-LTR, actin and metallothionein promoter sequences.
The preferred mollusks of the embodiments of the present invention are selected from the group consisting of Pinctada maxima, Pinctada mar ger it if era, Pinctada martensi fucata, Pinctada radiata, Pinctada vulgaris, Pinctada fucata, Pinctada maculata, Pinctada albina , Pteria penguin , Unionides sp. and Haliotis sp. For those embodiments comprising an acceptor mollusk and a donor mollusk, such mollusks are selected independently from this group.
DESCRIPTION OF THE PREFERRED EMBODIMENT I. General An object of the present invention is to provide methods of enhancing the growth of pearl producing mollusks as well as provide mollusks having such enhanced growth characteristics. These methods and mollusks are useful in the pearl culturing process to reduce processing time and increase size and number yields of pearl producing mollusks.
Mollusks which are particularly useful in the present invention include oyster species such as Pteria penguin, Pinctada maxima, Pinctada mar ger it if era, Pinctada martensi fucata, Pinctada radiata, Pinctada vulgaris, Pinctada fucata, Pinctada albina and Pinctada maculata . Other pearl-producing mollusks including abalone, from the Haliotis genus and fresh water mussels of the Unionides genus. See Taburiaux, supra. The term mollusk is used generically to include adult
mollusks, as well as juvenile, larval and embryonic forms thereof.
Mollusks having enhanced growth characteristics generally show an increase in one or more of the following characteristics compared with mollusks having normal growth characteristics: shell height, shell length, overall weight or tissue mass. An enhanced growth rate for a mollusk is the change in mass, length or height per unit time of about 1-150, 10-100 or 20-50% greater than that of a normal mollusk of similar size and age in a similar environment. For example, a normal oyster exhibiting an increase in shell length of lOmm/month, would have that rate of increase enhanced to from about 10.1 mm/month to about 25 mm/month.
Further, mollusks whose growth rate is enhanced also have increased periostracum formation and shell deposition over those mollusks without an enhanced growth rate. Such increased periostracum formation and shell deposition also increase the rate of nacre production which results in an increase in the rate of pearl formation. Additionally, mollusks having an enhanced growth rate, having achieved a larger size, are capable of harboring larger nuclei and/or pearls within their interior. Thus, pearls produced by a mollusk whose growth rate is enhanced or within tissue capable of expressing a growth enhancing agent according to the methods of the present invention generally have a diameter of from about 5 % to about 50 % greater than pearls formed by a mollusk whose growth rate is not enhanced, when cultured under similar conditions for a similar time period. Thus, where a pearl cultured in a nonenhanced growth mollusk is about 10 mm in diameter, a pearl cultured in a mollusk having an enhanced growth rate over the same period is from about 10.5 to about 15 mm in diameter. Alternatively, the mollusk having the enhanced growth rate produces a pearl of given diameter in diameter in about 5-30% less time than a mollusk having a normal growth rate.
Growth enhancing agents generally include those compounds which when exposed to living organisms, directly or indirectly induce the growth of the organism, thereby increasing the
organism's growth rate over and above the natural growth rate of that organism. Thus, compounds essential to the existence of the organism, i.e. nutrients, oxygen or water, are not included within the definition of growth enhancing agents. Examples of growth enhancing agents include growth hormones, growth factors, insulins and insulin-like peptides. Additionally, growth enhancing agents include those factors which induce the release of natural growth inducers within the mollusk. These endocrinological "triggers" result in increased expression of the mollusk's natural growth inducers, thus resulting in an enhanced growth rate. These triggers of growth related hormones have been described in other vertebrates.
Specific growth hormones which are useful in the present invention include fish growth hormones, i.e., rainbow trout (Agellon and Chen, DNA 5:463-471 (1986)), coho salmon (Villasenor, et al, Gene 65:239-246), and catfish (Tang, et al., Mol . Mar. Biol . and Biotech . , 2(4) :198-206) , as well as bovine, porcine and human growth hormones. Similarly, insulins which are particularly useful in the present invention include mammalian insulins, such as porcine, bovine and human insulin. See, e.g., Plisetskaya, et al., Gen . Comp . Endocrin . , 35:133-145 (1978), Morse, D.E., Aguaculture , 39:263-282 (1984). Insulin-like peptides, such as human and molluscan insulin-like peptides ("MIP") , are also useful as growth enhancing agents in the methods and mollusks of the present invention. See, e.g., Smit, et al., J. Mol . Endocrin . , 11:103-113 (1993), Smit, et al., Mol . Brain Research , 14:7-12 (1992). Also included are analogs or amino acid sequence variants of these agents.
II. Method for Enhancing Mollusk Growth by Transgenic
Expression of an Exogenous Growth Enhancing Agent and Mollusks Capable of Such Expression The invention provides methods for enhancing the growth rate of a mollusk and a mollusk having an enhanced growth rate. The mollusks are produced and the methods are practiced by introducing into the mollusk an exogenous nucleic acid
sequence which comprises a segment which encodes a growth enhancing agent operably linked to a promoter sequence, whereby the mollusk is capable of expressing the growth enhancing agent. A DNA segment is operably linked when placed into a functional relationship with another DNA segment. For example, a promoter or enhancer is operably linked to a coding sequence if it stimulates the transcription of the sequence; DNA for a signal sequence is operably linked to DNA encoding a polypeptide if it is expressed as a preprotein that participates in the secretion of the polypeptide. Generally, DNA sequences that are operably linked are contiguous, and in the case of a signal sequence both contiguous and in reading phase. However, enhancers need not be contiguous with the coding sequences whose transcription they control. Linking is accomplished by ligation at convenient restriction sites or at adapters or linkers inserted in lieu thereof.
An exogenous DNA segment is one foreign to the cell, or homologous to the cell, but in a position within the host cell genome in which the element is not ordinarily found. For example, exogenous DNA segments include heterologous nucleic acid sequences derived from species, genera, families and the like, other than the organism into which it is introduced. Exogenous DNA segments also include a homologous coding sequence operably linked to a heterologous promoter sequence, or alternatively, a heterologous coding sequence operably linked to a homologous promoter sequence. Exogenous DNA segments further include a multiple gene copy nucleic acid sequence where such is not present in the native genome. The presence of multiple copies can result in increased production of the growth enhancing agent relative to expression in the native genome. Exogenous DNA segments are expressed to yield exogenous polypeptides.
In preferred embodiments, the nucleic acid sequence encoding the growth enhancing agent is selected from the group of nucleic acids which encode growth hormones, insulins and insulin-like peptides. The nucleic acid sequences for a variety of growth hormones have been reported. See, e.g. ,
Agellon and Chen, DNA 5:463-471 (1986), Villasenor, et al, Gene 65:239-246, and Tang, et al., Mol . Mar. Biol . And Biotech . , 2(4) :198-206. The nucleic acid sequences for insulin related peptides, and specifically for Human and Molluscan Insulin-like Peptide, have also been reported. See, e.g., Smit, et al., J. Mol . Endocrin . , 11:103-113 (1993), Smit, et al., Mol . Brain Research , 14:7-12 (1992). Similarly, the nucleic acid sequences for various insulins, e.g., human, porcine and bovine, have been reported and are also available from GenBank. Other nucleic acids encoding growth enhancing agents of the present invention can be synthesized, or directly cloned from genomic libraries using, for example, PCR methods. See, e.g., Alberts, et al.. Molecular Biology of the Cell (2nd Ed. 1989), Sambrook, et al., Molecular Cloning: A Laboratory Manual (C.S.H.P. 2d ed. 1989). The nucleic acid sequence encoding the growth enhancing agent can be genomic, cDNA, minigene (i.e., genomic without selected intronic regions not required for expression) or a hybrid of any of these. Once cloned, the desired sequence is coupled to an appropriate promoter sequence. Promoter sequences useful in the present invention include those of prokaryotic or eucaryotic origin. Generally, promoters that are functional in mammalian cells are also functional in lower eucaryotic forms such as fish or mollusks. Preferred promoter sequences are the long terminal repeat sequence of the Avian Rous Sarcoma Virus (RSV-LTR) (see, e.g., Chen, et al., Mol . Marine Biol . and Biotech . , 2(2):88-95 (1993), Dunham, et al., Mol . Marine Biol . and Biotech . , 1(4/5) :380-389 (1992)), the inducible mouse metallothionein-I promoter, as well as the actin, pgk , tk, and dhfr promoters. Optionally, the coding sequence is operably linked to additional control sequences, such as an enhancer, a 3' and/or 5' untranslated region, a 3' and/or 51 flanking region, an intronic sequence, a signal sequence capable of directing secretion of the growth promoting factor from the cell in which it is expressed, and a polyadenylation site. Additional regulatory sequences are
often obtained from sequences naturally flanking the coding sequence of the growth promoting factor and/or the promoter.
In some transgenes, the sequence encoding the growth enhancing agent is fused in-frame to a second exogenous protein-coding sequence, such that the growth enhancing agent is expressed as a fusion protein. The presence of all or part of the second exogenous protein can enhance or facilitate the targeting, stability, acceptance and/or processing of the growth enhancing agent within the cells of the mollusk. Nucleic acid sequences are introduced into the germline of a mollusk embryo to generate a transgenic mollusk. A transgenic mollusk is one in which all of the somatic and germline cells (with the possible exception of a few cells subject to somatic mutation) contain at least one copy of an integrated transgene, the transgene having been introduced into the germline of the mollusk or an ancestor of the mollusk at an early embryonic stage. For example, the nucleic acid can be introduced into individual mollusk embryos at the one- cell (i.e., zygote) or two-cell stage. Introducing DNA at the one-cell stage results in a higher probability of germline incorporation. Incorporation at later stages often results in a mosaic mollusk, only some of whose cells have integrated the transgene. Subsequent breeding is then required to isolate true transgenic mollusks. Methods of introducing exogenous nucleic acid sequences into embryonic cells include microinjection (see U.S. Patent No. 4,873,292), electroporation, viral transduction and the like. For example, nucleic acids encoding growth enhancing agents can be introduced into mollusks using the same procedure as described for introducing such nucleic acids into t-ransgenic fish. See, e.g., Dunham, et al., supra, Chen, et al., supra. Alternatively, the exogenous nucleic acid segment is introduced into the mollusk by electroporation of a fertilized mollusk egg. The conditions for electroporation are the same as those conventionally used for electroporation of nucleic acids into mammalian cells. See Sambrook et al., supra. Occasionally, incorporation of an exogenous DNA disrupts an important cellular function. However, such
mollusks are easily eliminated, either by premature death, deformity or other distinguishable features such as reduced size and weight.
The presence of an integrated transgene in the genome of a mollusk is confirmed by extracting DNA from a tissue biopsy and analyzing the DNA for the presence of the nucleic acid sequence, e.g., by Southern analysis of DNA using probes specific for the exogenous nucleic acid sequence of the growth enhancing agent. Expression of the transgene is confirmed by Northern analysis of RNA from the biopsy using a similar probe. Alternatively, a protein extract of the biopsy is analyzed by Western blotting, radioimmunoassay or ELISA using an antibody to the growth enhancing factor being expressed as the probe. True transgenic status is established by transmission of the transgene from PI mollusks to FI progeny. The PI mollusks can be bred either with other PI mollusks or with nontransgenic mollusks. Interbreeding of transgenic mollusks can be used to establish a mollusk line that is homozygous for the integrated transgene.
III. Methods of Culturing Pearls
The invention provides methods for culturing pearls by enhancing the growth of the mollusks involved in the pearl culturing process. In modern commercial pearl culturing, a foreign body, or "nucleus" is introduced or implanted into the gonadal tissue of a mollusk. The mollusk receiving this nucleus is termed the mother or acceptor mollusk. Nuclei include any foreign body around which the mollusk produces a nacre. Such nuclei are generally small rounded objects, such as fragments of shells from other mollusks, metallic spheres, or other similarly shaped objects. The size and shape of such nuclei depends upon the size and shape of the pearl desired. Thus the invention provides custom shaped nuclei for producing pearls of any desired shape. Generally, a piece of tissue from the mantle portion of a mollusk is also implanted in the gonadal tissue of the acceptor mollusk along with the nucleus. The mollusk from which this mantle tissue is derived, is termed the "donor"
mollusk. Although generally the mantle tissue is taken from a separate donor mollusk, the mantle tissue can be derived from the acceptor mollusk and reimplanted along with the nucleus in the gonadal tissue of that acceptor mollusk. Thus, in some instances, the acceptor mollusk can also be the donor mollusk. Similarly, although preferably the acceptor mollusk and the donor mollusk are the same species, this need not be the case. The implantation of the nucleus and donor mantle tissue is carried out by conventional methods routine in pearl culturing processes.
Optionally, a nucleus can be implanted between the shell and mantle of the acceptor mollusk, e.g. , in the production of mabe pearls. Where this is the case, the implantation of the donor mantle tissue can be omitted.
A. Exposing Mollusks to Exogenous Growth Enhancing
Agent One embodiment of the present invention provides a method for culturing pearls comprising exposing pre-adult mollusks, e.g., juvenile, spat or larval mollusks, to an effective amount of a growth enhancing agent, whereby the growth rate of the mollusk is enhanced. When the mollusk reaches adult size, a nucleus and optionally, mantle tissue from a donor mollusk is introduced into the mollusk. The mollusk is then cultured and pearls are harvested therefrom. Whether a mollusk has reached adult size is dependent upon industry standards for a particular pearl producing mollusk, and as a result, varies from species to species. For example, the larger species of Haliotis have a larger adult size than the more typical Pinctada maxima oyster species.
The raising of mollusk spat for use in pearl culturing processes, herein termed "preculturing, " can take upwards of 24 months. The present invention expedites the preculturing aspect of pearl culturing by enhancing the growth rate of juvenile or larval mollusks. As described for other aspects of the instant invention, the exposing of mollusk spat to an effective amount of growth enhancing agent can comprise immersing the spat in a solution comprising growth enhancing
agent at a concentration of from about 1 X 10~9 M (InM) to about 1 X 10"2 M (lOmM) . More preferred are solutions wherein the growth enhancing agent is present in a concentration of from about 1 X 10"6 M (lμM) to about 1 X 10"4 M (lOOμM) . Further, such immersion treatments should preferably comprise immersing the spat in the composition comprising the growth enhancing agent for from about 30 minutes to about 10 hours, and can be carried out as frequently as necessary to achieve the desired results. Preferably, such treatments are carried out daily, semi-weekly, weekly, biweekly or monthly during a portion of, or throughout the preculturing process.
In another embodiment, the present invention provides a method of culturing pearls comprising the steps of introducing into an acceptor mollusk, a nucleus and, optionally, mantle tissue from a donor mollusk, and exposing the acceptor mollusk to an effective amount of a growth enhancing agent. The acceptor mollusk is then cultured, and pearls are harvested therefrom. Again, where the nucleus is implanted between the oyster shell and the mantle of the acceptor mollusk, the implantation of mantle tissue from the donor mollusk can be omitted.
The exposing of the acceptor mollusk to the growth enhancing agent may take a variety of forms. In one embodiment, the implanted acceptor mollusk to be exposed to the growth enhancing agent is immersed in a solution which comprises an effective amount of the growth enhancing agent. This immersion treatment is carried out in substantially the same fashion as the treatment described for juvenile or larval oysters. Again, these treatments are preferably carried out daily, semi-weekly, weekly, biweekly or monthly during a portion of, or throughout the pearl culturing process. More preferably, the treatments are carried out during the natural growing season of the mollusk.
In an alternative embodiment, the solution comprising an effective amount of the growth enhancing agent described above is manually introduced between the valves of the implanted acceptor mollusk. In one embodiment, the solution comprising the growth enhancing agent as described above is directly
injected into the body or pallial space of the mollusk. While these injections are generally carried out on an implanted acceptor mollusk, these injections may be performed prior to implantation. These injections can be carried out by a number of methods, i.e., inserting a syringe needle between the opposing valves of the acceptor mollusk (a natural gap exists between valves in some oyster species, i.e., Pinctada maxima) , filing a notch to produce a small hole in the junction of the two valves, or drilling a small hole in a valve so as to allow the injection of growth enhancing agent between the valves. Preferably, the solution comprising the growth enhancing agent is injected in a volume of from about 0.5 to about 2.0 mL. More preferably, the injection is into the pallial or extrapallial spaces of the mollusk so as not to penetrate the organs or tissue which comprise the body of the mollusk. Again, the injection treatments are carried out daily, semi-weekly, weekly, biweekly or monthly.
Effective amounts of growth enhancing agents in the above described solutions vary with the particular growth enhancing agent used. In general, effective amount is defined as a combination of concentration of growth enhancing agent in the solution to which the mollusk is exposed, the length of the individual exposure treatments and number and frequency of exposure treatments. The growth enhancing agents are usually present in the above described solutions at a concentration of about 1 X 10"9 M (lnM) to about 1 X 10"2 M (lOmM) . More preferred are solutions wherein the growth enhancing agent is present in a concentration of from about 1 X 10"6 M (1 μM) to about 1 X 10" 4 M (100 μM) . Preferably, the growth enhancing agent is dispersed in seawater or other appropriate saline solutions.
In a related embodiment, the present invention also provides for the insertion of a controlled release composition comprising a growth enhancing agent in the tissue of the implanted acceptor mollusk. Controlled release compositions are generally in the form of a tablet, capsule or liposome such that the composition is retained within the tissue of the mollusk while releasing a constant low level of the growth
enhancing agent. These controlled release compositions generally incorporate the growth enhancing agent in a matrix such that the composition can release effective amounts of the growth enhancing agent over a sustained period of time. Specifically, the growth enhancing agents are contained within beads, capsules, or microcapsules, surrounded by a barrier which degrades slowly over time to sustain a constant, low level release of the growth enhancing agent into the surrounding environment, without producing degradation products harmful to the mollusk. Compositions useful as barriers are generally commercially available and include, for example, those compositions which are generally used in pharmaceutical applications. See Heller et al., Advanced Drug Delivery Rev . 10:163-204 (1993) and Tyrrell et al., Biochim . Biophys . Acta 457:259-302 (1976). Alternatively, the growth enhancing agents can also be adsorbed to a matrix whereby the growth enhancing agent is slowly released from the matrix in the culturing environment.
Preferably, the controlled release compositions are inserted into the body or tissue of the acceptor mollusk.
Preferably, the controlled release composition can be inserted directly into the gonadal tissue of the mollusk so as to create a region of higher concentration of the growth enhancing agent in the immediate area of pearl formation. In addition to allowing exposure of the acceptor mollusk to the growth enhancing agent with minimal manual manipulation of the mollusk, the slow dissolving nature of these controlled release compositions prevents them from acting as a nucleus for nacre formation. Following culturing, pearls are harvested from the acceptor mollusks by conventional methods. These mollusks can then be reimplanted for repeated pearl culturing, if desired.
B. Pearl Culturing with Transgenic Mollusks Capable of Expressing Growth Enhancing Agents
As described previously, the modern pearl culturing process generally comprises the implantation or insertion of a nucleus and a piece of mantle tissue into the gonadal tissue
of the acceptor mollusk. However, this process may vary, for example, where mabe pearls are desired.
In a particular embodiment of the present invention, the nucleus and mantle tissue from a donor mollusk are implanted into a transgenic acceptor mollusk. The transgenic acceptor mollusk comprises an exogenous nucleic acid sequence which comprises a segment encoding a growth enhancing agent operably linked to a promoter sequence. The transgenic acceptor mollusk is thereby capable of expressing the growth enhancing agent.
Alternatively, the mantle tissue which is implanted into the acceptor mollusk is obtained from a transgenic donor mollusk. The donor mollusk then comprises the exogenous nucleic acid sequence comprising a segment encoding a growth enhancing agent operably linked to a promoter sequence. The implanted cells from the donor mollusk are thus capable of expressing the growth enhancing agent. This particular embodiment is particularly useful where it is desirable to avoid releasing a transgenic mollusk species into the environment. Therefore, this embodiment is readily be practiced on the scale of a commercial pearl culturing operation.
Although the above embodiments are stated in terms of either a transgenic acceptor mollusk or a transgenic donor mollusk, either or both the acceptor and donor mollusks can be transgenic, i.e., capable of expressing an exogenous growth enhancing agent.
The present invention is further illustrated by the following examples. These examples are merely to illustrate aspects of the present invention and are not intended as limitations of this invention.
EXAMPLES All reagents used herein are available commercially unless otherwise noted.
Example 1: General Oyster Production
For a number of the following examples, oysters at various stages of development are used. Accordingly, the initial example describes the raising and culturing of oysters from egg cells to adult oysters.
Typical broodstock oysters are collected from the wild just prior to the natural spawning season. These oysters are kept in flow through or recirculating seawater at temperatures just below the natural spawning temperature. These are typically from about 25 to about 30°C. When judged to be in spawning condition by visual inspection of the gonads, the temperature is increased by from about 5°C to about 8°C. This temperature increase usually induces spawning.
Upon induction of spawning, oysters are identified as male or female and placed in separate vessels accordingly.
When spawning is complete, the oysters are removed from their respective tanks, and the sperm and egg suspensions are collected and mixed. Once fertilized, the eggs are transferred to another tank to begin the larval culture. Fertilized eggs are stocked at a density of from about 20 to about 30 eggs per ml and kept in aerated tanks for 24 to 48 hours, during which time the eggs hatch. The larvae from the eggs are collected on sieves and placed in tanks at a density of about 20 larvae per ml, and fed algae. The feed is typically a mixture of diatoms and Isochrysis galbana , at a density of 20,000 to 30,000 cells/ml in the larval tanks.
As the larvae grow, their densities are reduced. Typically, when the larvae reach pediveliger stage, their density is reduced to 2 to 3 per ml. For metamorphosis, some species require addition of a substrate upon which to attach •during the process, while others simply settle to the bottom of the tank. Metamorphosis may be chemically induced in some species.
Following metamorphosis, the young oysters, now termed spat, are moved into flow through containers, e.g., upwellers or downwellers, and fed by coarsely filtered seawater until reaching adulthood.
Example 2: Immersion
A. Enhancing Spat Growth
In order to assess the effect of growth promoters on juvenile oysters, the following experiment was performed: Juvenile pearl oysters (Pinctada margeritifera) approximately 1 mm in length, were obtained from a commercial source. These juveniles were maintained in closed recirculating aquaria at 28°C, and fed Thallasiosira and Isochrysis . A subset of the juveniles was immersed in seawater containing 10"6M insulin while another group was immersed in seawater alone. After one week, the treated group showed 30% greater growth than the untreated group. Continued weekly immersions resulted in continued accelerated growth of the juveniles over that of the untreated group. No mortality was observed in either group.
B. Enhancing Acceptor Shell Growth and Pearl Production Adult oysters of approximately the same age are obtained from commercial hatcheries. A spherical nucleus having a diameter of 10 mm, and a 25 mm2 sample of mantle tissue from another adult oyster is implanted into these oysters. Half of the oysters given these implants are treated by immersion in a ten fold volume of filtered ambient seawater containing from about 10 μM porcine insulin. The treatment is carried out every 14 days throughout the growing season and ceased in nongrowing periods. The remaining half is the control group, subject to the same manipulations but absent any insulin contact.
After treatment for 12 months, the oysters in the treated group show a greater growth percentage than the oysters in the nontreated group. The oysters of both groups are opened and the pearls produced therein are harvested, dried, weighed and their diameter is measured. Pearls obtained from the oysters subject to the treatment with insulin show greater dry weight and larger diameter than those produced by the control group.
Example 3: Controlled Release Composition
A slow-release insulin capsule such as described by Heller, supra is inserted into the tissue or gonad of a test group of oysters. Concurrently with the insertion of the insulin capsule, a nucleus of 10 mm in diameter and a 25 mm2 sample of mantle tissue from a donor oyster are inserted into a separate incision in the gonadal tissue of the test oyster. The oysters are closed and returned to normal culture conditions. After culturing for 12 months, the test oysters are opened and their pearls are harvested. Pearls harvested from these test oysters have a larger diameter and a greater dry weight than pearls produced by the control group.
Example 4: Injection of the Growth Enhancing Agent Juvenile Pinctada maxima oysters are removed from their culture conditions. An 18-gauge needle is inserted through the dorsal notch into the pallial space of each oyster. One ml of lOOμM insulin solution is injected into the oyster. The injected oysters are held out of the water for one hour. After treatment, the oysters are returned to their normal culture conditions. The injections are repeated every 14 days during the growing season. After 12 months, the oysters show greater percent growth than the oysters of the control group.
Example 5: Generating Transgenic Oysters
The cDNA sequence of human insulin has been described. See, Gen Bank Ace. No. L15440. The cDNA coding sequence including 3• and 5' untranslated regions and a polyadenylation signal is modified by the addition of Sail linkers and ligated to a Rous Sarcoma Virus long terminal repeat (RSV-LTR) promoter/enhancer sequence at the Sail site in a pRSV-2 vector, as described by Gorman et al, Proc. Natl Acad. Sci. (USA) 79:6777-6781 (1982). The cDNA coding sequence is thereby linked to 580 bp of the LTR sequence and 3.7 kb of pRSV flanking sequence. After propagation of the vector, the vector is linearized to provide a transgene suitable for injection.
The linearized transgene is electroporated into fertilized eggs from Pinctada maxima obtained from a commercial hatchery or by laboratory spawning and fertilization. The eggs are cultured to spat and juvenile oysters. The presence of the RSV-LTR-Insulin transgene is assayed from a biopsy of the oyster tissue. Chromosomal DNA is extracted and amplified using primers hybridizable to the transgene. The amplification product is detected by gel electrophoresis. Expression of human insulin is detected by Western blotting of a protein extract from the biopsy. Founder transgenic oysters are interbred to generate transgenic progeny, whose transgenic status and expression is assayed using the same methods as described for the founder oysters. Juvenile transgenic oysters which express the human insulin sequence are cultured under the same conditions as a control group of normal oysters of approximately equal size and age. After culturing for 12 months, the transgenic oysters show a higher percent growth than the oysters of the control group.
Example 6: Pearl Culturing Using Transgenic Oysters
To show the effects of the expression of growth enhancing agents on the pearl culturing process, two subsets of oysters are provided. Set 1 comprises the oysters of Example 5 which demonstrate enhanced growth rates relative to the control group. Set 2 comprises "normal" Pinctada maxima oysters, i.e., nontransgenic oysters.
The oysters are implanted with a spherical nucleus 10 mm in diameter, and a 25 mm2 sample of donor mantle tissue. The following sets of acceptor oysters results:
1. Transgenic acceptor oyster, normal donor oyster.
2. Normal acceptor oyster, transgenic donor oyster.
3. Transgenic acceptor oyster, transgenic donor oyster. 4. Normal acceptor oyster, normal donor oyster
(control) .
The acceptor oysters are cultured in a marine environment for 12 months. At the completion of the culturing process.
the pearls obtained from the oysters of groups 1, 2 and 3 are larger in diameter and have a greater dry weight than those produced by the control group.
While the foregoing invention has been described in some detail for purposes of clarity and understanding, it will be clear to one skilled in the art from a reading of this disclosure that various changes in form and detail can be made without departing from the true scope of the invention. All publications and patent documents cited in this application are incorporated by reference in their entirety for all purposes to the same extent as if each individual publication or patent document were so individually denoted.
Claims
1. A method of enhancing the growth of a pearl producing mollusk, said method comprising introducing into the germline of said mollusk a nucleic acid sequence, said nucleic acid sequence comprising a segment which encodes a growth enhancing agent, said segment being operably linked to a promoter sequence whereby said segment is capable of expressing said growth enhancing agent in said mollusk.
2. The method of claim 1, wherein said mollusk is selected from the group consisting of Pteria penguin, Pinctada maxima, Pinctada margeritifera, Pinctada martensi fucata, Pinctada radiata, Pinctada vulgaris , Pinctada fucata, Pinctada maculata, Pinctada albina, Unionides sp . and Haliotis sp .
3. The method of claim 1, wherein said growth enhancing agent is selected from the group consisting of insulin, molluscan insulin-like peptide and growth hormone.
4. The method of claim 1, wherein said promoter sequence is an RSV-LTR or mouse metallothionein-I promoter sequence.
5. A transgenic mollusk, said mollusk having a germline comprising an exogenous nucleic acid sequence, said exogenous nucleic acid sequence comprising a segment which encodes a growth enhancing agent, said segment being operably linked to a promoter sequence, and wherein said segment is capable of expressing said growth enhancing agent in said mollusk.
6. The transgenic mollusk of claim 5, wherein said promoter sequence is an RSV-LTR or mouse metallothionein-I promoter sequence.
7. The transgenic mollusk of claim 5, wherein said growth enhancing agent is selected from the group consisting of insulin, molluscan insulin-like peptide and growth hormone.
8. The transgenic mollusk of claim 5, wherein said mollusk is selected from the group consisting of Pteria penguin, Pinctada maxima, Pinctada margeritifera, Pinctada martensi fucata, Pinctada radiata, Pinctada vulgaris, Pinctada fucata, Pinctada maculata , Pinctada albina , Unionides sp. and Haliotis sp.
9. A method of culturing pearls comprising: (a) introducing a nucleus into an acceptor mollusk; (b) exposing said acceptor mollusk to an effective amount of a growth enhancing agent; (c) culturing said acceptor mollusk; and (d) harvesting pearls from said acceptor mollusk.
10. The method of claim 9, further comprising introducing into said acceptor mollusk, mantle tissue from a donor mollusk.
11. The method of claim 10, wherein said acceptor mollusk and said donor mollusk are selected independently from the group consisting of Pinctada maxima, Pinctada margeritifera, Pinctada martensi fucata, Pinctada radiata, Pinctada vulgaris, Pinctada fucata , Pinctada maculata, Pinctada albina, Unionides sp. and Haliotis sp.
12. The method of claim 9, wherein said acceptor mollusk is exposed to said growth enhancing agent by immersing said acceptor mollusk in a solution comprising said growth enhancing agent at a concentration of from about l nM to about 10 mM of the growth enhancing agent.
13. The method of claim 9, wherein said acceptor mollusk is exposed to said growth enhancing agent by immersing said mollusk in a solution comprising said growth enhancing agent at a concentration of from about 0.1 μM to about 100 μM of the growth enhancing agent.
14. The method of claim 9, wherein said acceptor mollusk is exposed to said growth enhancing agent by introducing a composition comprising said growth enhancing agent into the interior of said acceptor mollusk.
15. The method of claim 14, wherein said introducing of said composition comprises injecting said composition into the interior of said acceptor mollusk.
16. The method of claim 14, wherein said composition comprising said growth enhancing agent is a controlled release composition.
17. The method of claim 9, wherein said growth enhancing agent is selected from the group consisting of insulin, molluscan insulin-like peptide, and growth hormone.
18. A method of culturing pearls comprising: (a) introducing into an acceptor mollusk, a nucleus and mantle tissue from a donor mollusk, said donor mollusk having a germline comprising a nucleic acid sequence which encodes a growth enhancing agent, said sequence being operably linked to a promoter sequence whereby said segment is capable of expressing said growth enhancing agent in said mollusk; (b) culturing said acceptor mollusk; (c) harvesting pearls from said acceptor mollusk.
19. The method of claim 18, wherein said acceptor mollusk and said donor mollusk are selected independently from the group consisting of Pteria penguin, Pinctada maxima, Pinctada margeritifera, Pinctada martensi fucata, Pinctada radiata, Pinctada vulgaris, Pinctada fucata; Pinctada maculata, Pinctada albina , Unionides sp. and Haliotis sp.
20. The method of claim 18, wherein said growth enhancing agent is selected from the group consisting of insulin, molluscan insulin-like peptide and growth hormone.
21. The method of claim 19, wherein said promoter sequence is an RSV-LTR or a mouse metallothionein-I promoter sequence.
22. A method of culturing pearls comprising: (a) introducing a nucleus into an acceptor mollusk, said acceptor mollusk having a germline comprising a nucleic acid sequence, said nucleic acid sequence comprising a segment which encodes a growth enhancing agent, said segment being operably linked to a promoter sequence whereby said segment is capable of expressing said growth enhancing agent in said acceptor mollusk; (b) culturing said acceptor mollusk; and (c) harvesting pearls from said acceptor mollusk.
23. The method of claim 22, further comprising introducing into said acceptor mollusk, mantle tissue from a donor mollusk.
24. The method of claim 22, wherein said growth enhancing agent is selected from the group consisting of insulin, insulin-like growth factor and growth hormone.
25. The method of claim 22, wherein said promoter sequence is an RSV-LTR or a mouse metallothionein-I promoter sequence.
26. The method of claim 23, wherein said acceptor mollusk and said donor mollusk are selected, independently, from the group consisting of Pteria penguin , Pinctada maxima, Pinctada margeritifera, Pinctada martensi fucata, Pinctada radiata, Pinctada vulgaris, Pinctada fucata, Pinctada maculata, Pinctada albina, Unionides sp. and Haliotis sp.
27. A method of culturing pearls comprising: (a) exposing a mollusk to an effective amount of a growth enhancing agent, whereby the growth rate of said mollusk is enhanced; (b) introducing a nucleus into said mollusk; (c) culturing said mollusk; (d) harvesting pearls from said mollusk.
28. The method of claim 27, further comprising introducing into said mollusk, mantle tissue from a donor mollusk.
29. The method of claim 28, wherein said mollusk and said donor mollusk are selected independently from the group consisting of Pteria penguin, Pinctada maxima, Pinctada margeritifera, Pinctada martensi fucata, Pinctada radiata, Pinctada vulgaris, Pinctada fucata, Pinctada maculata, Pinctada albina, Unionides sp. , and Haliotis sp .
30. The method of claim 27, wherein said mollusk is exposed to said growth enhancing agent by immersing said mollusk in a solution comprising said growth enhancing agent at a concentration of from about 1 nM to about 10 mM of the growth enhancing agent.
31. The method of claim 27, wherein said growth enhancing agent is selected from the group consisting of insulin, molluscan insulin-like peptide and growth hormone.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US34220394A | 1994-11-18 | 1994-11-18 | |
US342203 | 1994-11-18 | ||
PCT/US1995/014685 WO1996015662A1 (en) | 1994-11-18 | 1995-11-06 | Enhancing growth and pearl production in mollusks |
Publications (2)
Publication Number | Publication Date |
---|---|
EP0792098A1 true EP0792098A1 (en) | 1997-09-03 |
EP0792098A4 EP0792098A4 (en) | 2002-11-05 |
Family
ID=23340806
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP19950940687 Withdrawn EP0792098A4 (en) | 1994-11-18 | 1995-11-06 | Enhancing growth and pearl production in mollusks |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP0792098A4 (en) |
JP (1) | JP2002502229A (en) |
AU (1) | AU713205B2 (en) |
NZ (1) | NZ297240A (en) |
WO (1) | WO1996015662A1 (en) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU740823B2 (en) * | 1997-11-17 | 2001-11-15 | Aotearoa Pearls Ltd | Nucleus and method for producing half or mabe pearls |
JP3803499B2 (en) * | 1999-02-25 | 2006-08-02 | 三木 敬三郎 | Transgenic pearl oyster and method for producing the same |
FR2838023B1 (en) * | 2002-04-05 | 2005-07-15 | Robert Wan Holding | PROCESS FOR PRODUCING PERLARIAN CULTURE GRAFTS |
WO2010120002A1 (en) | 2009-04-14 | 2010-10-21 | 한국해양연구원 | Black-lip pearl oyster egg extract, and method for assessing the productive effort of a black-lip pearl oyster using a black-lip pearl oyster egg extract-specific polyclonal antibody |
CN104839053B (en) * | 2014-12-30 | 2018-06-19 | 绍兴文理学院 | A kind of rapid induction pearl culturing clam pearl sac forms and promotes the method for pearl growth |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5076208A (en) * | 1990-09-14 | 1991-12-31 | Massachusetts Institute Of Technology | Ultrasound-mediated administration of compounds into aquatic animals |
WO1995020872A1 (en) * | 1994-02-04 | 1995-08-10 | The Board Of Trustees Of The Leland Stanford Junior University | Genetic engineering of mollusks |
-
1995
- 1995-11-06 NZ NZ297240A patent/NZ297240A/en unknown
- 1995-11-06 WO PCT/US1995/014685 patent/WO1996015662A1/en not_active Application Discontinuation
- 1995-11-06 JP JP51693996A patent/JP2002502229A/en active Pending
- 1995-11-06 EP EP19950940687 patent/EP0792098A4/en not_active Withdrawn
- 1995-11-06 AU AU42354/96A patent/AU713205B2/en not_active Ceased
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5076208A (en) * | 1990-09-14 | 1991-12-31 | Massachusetts Institute Of Technology | Ultrasound-mediated administration of compounds into aquatic animals |
WO1995020872A1 (en) * | 1994-02-04 | 1995-08-10 | The Board Of Trustees Of The Leland Stanford Junior University | Genetic engineering of mollusks |
Non-Patent Citations (5)
Title |
---|
PAYNTER K T: "IN-VITRO ASSESSMENT OF GROWTH RATE ON OYSTER TISSUES THE EFFECTS OF VERTEBRATE GROWTH HORMONE AND INSULIN" JOURNAL OF SHELLFISH RESEARCH, vol. 10, no. 1, 1991, pages 280-281, XP001105255 ISSN: 0730-8000 * |
POWERS D A ET AL: "ELECTROPORATION AS AN EFFECTIVE MEANS OF INTRODUCING DNA INTO ABALONE (HALIOTIS RUFESCENS) EMBRYOS" MOLECULAR MARINE BIOLOGY AND BIOTECHNOLOGY, XX, XX, vol. 4, no. 4, 1995, pages 369-376, XP000918527 * |
See also references of WO9615662A1 * |
SHAO JUN DU ET AL: "GROWTH ENHANCEMENT IN TRANSGENIC ATLANTIC SALMON BY THE USE OF AN ALL FISH CHIMERIC GROWTH HORMONE GENE CONSTRUCT" BIO/TECHNOLOGY, NATURE PUBLISHING CO. NEW YORK, US, vol. 10, no. 2, 1 February 1992 (1992-02-01), pages 176-181, XP000293043 ISSN: 0733-222X * |
WADA KOJI: "Genetical and physiological control of calcification in pearl cultivation." BULLETIN DE L'INSTITUT OCEANOGRAPHIQUE (MONACO), no. SPEC. ISSUE 14 PART 4, 1996, pages 183-193, XP001105861 ISSN: 0304-5722 * |
Also Published As
Publication number | Publication date |
---|---|
NZ297240A (en) | 1999-10-28 |
AU713205B2 (en) | 1999-11-25 |
AU4235496A (en) | 1996-06-17 |
EP0792098A4 (en) | 2002-11-05 |
JP2002502229A (en) | 2002-01-22 |
WO1996015662A1 (en) | 1996-05-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Devlin et al. | Transmission and phenotypic effects of an antifreeze/GH gene construct in coho salmon (Oncorhynchus kisutch) | |
Lim et al. | Use of the rotifer, Brachionus calyciflorus Pallas, in freshwater ornamental fish larviculture | |
Carroll et al. | Laboratory culture of the aeolid nudibranch Berghia verrucicornis (Mollusca, Opisthobranchia): some aspects of its development and life history | |
CN102046005B (en) | Mass production method for chromobotia macracanthus | |
KR101797784B1 (en) | Maternally induced sterility in animals | |
Arimoro | Culture of the freshwater rotifer, Brachionus calyciflorus, and its application in fish larviculture technology | |
US20050149997A1 (en) | Sterilization of marine organisms by manipulation of DNA content | |
US6015713A (en) | Transgenic fish and a method of harvesting islet cells therefrom | |
Giraspy et al. | Australia’s first commercial sea cucumber culture and sea ranching project in Hervey Bay, Queensland, Australia | |
US6476290B1 (en) | Transgenic tilapia comprising a humanized insulin gene | |
CN108377936A (en) | A kind of large-scale method for producing of complete female mandarin fish | |
AU713205B2 (en) | Enhancing growth and pearl production in mollusks | |
Keesing et al. | Large-scale laboratory culture of the crown-of-thorns starfish Acanthaster planci (L.)(Echinodermata: Asteroidea) | |
YOSHIZAKI | Gene transfer in salmonidae: applications to aquaculture | |
Liu et al. | The clam, Xishi tongue Coelomactra antiquata (Spengler), a promising new candidate for aquaculture in China | |
KR100692378B1 (en) | Tintinnid, Undella sp. Chuuk-04 Available For Hatched Fry Feed And Culturing Method Thereof | |
CN105941223A (en) | A culture method for piaractus brachypomus | |
Kurbanov et al. | Maturation of African catfish, Clarias gariepinus, in condition of seasonal climate of Uzbekistan | |
US20220090126A1 (en) | Transgenic barb | |
US20080070289A1 (en) | Process for storing enriched nematodes | |
Dunham et al. | Transgenic fish–where we are and where do we go? | |
JP5688849B2 (en) | Transgenic goldfish | |
CN115305260B (en) | Microinjection method and application of fertilized eggs of golden pomfret | |
CN100378220C (en) | Novel transgenic medaka, gene fragments | |
CN113016669B (en) | Domestication method for pomfret completely ingesting pellet feed |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 19970618 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): CH DE FR GB IT LI NL |
|
A4 | Supplementary search report drawn up and despatched | ||
AK | Designated contracting states |
Kind code of ref document: A4 Designated state(s): CH DE FR GB IT LI NL |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20021105 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20030524 |